IGF-1 LR3 Dosage: How Much to Take, When & How
Overview
IGF-1 LR3 is a synthetic peptide analog with an extended half-life of 20–30 hours, making it significantly more bioactive than native IGF-1. The standard dosing range for research and illicit athletic use is 20–100 mcg administered once daily via subcutaneous or intramuscular injection. Cost typically ranges from $30–$120 per month, depending on source and purity.
This guide addresses practical dosing considerations: frequency, administration routes, cycling protocols, and dose adjustments based on individual goals. Important disclaimer: IGF-1 LR3 is not approved for human use in any jurisdiction and is classified as a research chemical. This content is educational only and does not constitute medical advice. Consult a healthcare provider before use, especially if you have a personal or family history of cancer, diabetes, or cardiovascular disease.
Standard Dosing Protocol
The established dosing range for IGF-1 LR3 is 20–100 mcg once daily. Most users operate within this window, though exact dose depends on experience level, body weight, and specific goals.
Standard Entry Dose:
- 20–40 mcg daily for beginners or those assessing tolerance
- Administered as a single subcutaneous injection, typically in the morning or post-workout
- This range minimizes acute hypoglycemia risk while allowing observation of individual response
Intermediate Dose:
- 40–60 mcg daily for experienced users with established tolerance
- Divided dosing (e.g., 30 mcg AM, 30 mcg PM) is common among athletes, though once-daily administration is standard
- Maintains efficacy without excessive receptor saturation
Advanced Dose:
- 60–100 mcg daily for experienced users pursuing maximal muscle growth
- Typically split into two doses (e.g., 50 mcg AM, 50 mcg PM) to sustain plasma levels given the 20–30 hour half-life
- Higher risk of side effects, particularly hypoglycemia and soft tissue overgrowth
- Requires strict cycling protocols to prevent receptor desensitization
Dosing by Goal
Muscle Growth
Evidence supports IGF-1 LR3's theoretical anabolic potential, though human efficacy data is absent. Animal studies demonstrate increased myoblast proliferation and muscle protein synthesis at doses significantly higher than those used clinically.
Muscle Growth Protocol:
- Start: 40 mcg daily
- Maintenance: 50–100 mcg daily in divided doses (25–50 mcg × 2)
- Cycle Duration: 4–8 weeks on, 2–4 weeks off
- Best Timing: Administer one dose post-workout (30–60 minutes after training) to coincide with elevated nutrient sensitivity and increased IGF-1R expression in muscle tissue
Rodent data showing maximal effect used systemic doses of 280 mcg in encapsulated form, but human experience suggests lower peripheral doses are effective and safer.
Fat Loss & Body Composition
Animal studies show IGF-1 LR3 preferentially preserves muscle during caloric restriction, though no human fat loss trials exist. The mechanism involves anti-catabolic signaling and improved nutrient partitioning.
Fat Loss Protocol:
- Start: 20–30 mcg daily
- Maintenance: 30–50 mcg daily as a single morning dose
- Cycle Duration: 6–12 weeks on, 2–4 weeks off
- Best Timing: Morning injection on an empty stomach (or with minimal carbohydrates) to maximize lipolytic effects
Lower doses suffice for body composition goals compared to pure muscle growth, reducing hypoglycemia risk.
Recovery & Injury Prevention
Limited animal evidence suggests IGF-1 LR3 accelerates nerve regeneration and muscle repair, though clinical efficacy in humans remains unproven.
Recovery Protocol:
- Start: 20–40 mcg daily
- Maintenance: 30–50 mcg daily
- Cycle Duration: 4–6 weeks on, 2–3 weeks off
- Best Timing: Post-workout injection or evening dose to align with natural recovery windows
How to Administer
Injection Technique
IGF-1 LR3 is administered exclusively via injection—subcutaneous (subQ) or intramuscular (IM)—as it is peptide-based and rapidly degraded orally.
Subcutaneous Injection (Most Common):
- Use 0.5–1 mL tuberculin or insulin syringe with 27–31 gauge needle
- Rotate injection sites: abdomen, thigh, shoulder, or glutes to minimize localized lipohypertrophy
- Pinch skin, insert needle at 45° angle, inject slowly (2–3 seconds)
- Withdraw needle and apply light pressure; do not massage
Intramuscular Injection:
- Use 1–3 mL syringe with 25 gauge needle
- Deltoid, quadriceps, or glute injection sites preferred
- Insert at 90° angle, aspirate to confirm non-vascular placement, inject over 3–5 seconds
- IM injection may produce faster absorption but offers no additional benefit over subQ for IGF-1 LR3
Preparation & Storage
- Reconstitution: Most commercial IGF-1 LR3 arrives as lyophilized powder. Reconstitute with bacteriostatic water (not normal saline) at a ratio appropriate to desired concentration (typically 1 mg per 1 mL water for 1000 mcg/mL stock)
- Storage: Keep reconstituted peptide refrigerated at 2–8°C (36–46°F). Stability is typically 3–4 weeks under proper refrigeration
- Sterility: Use a new sterile needle for each injection; never share needles
Dose Measurement
- Pre-fill syringes or use insulin pins marked in units if your supplier provides pre-calibrated vials
- Example: If reconstituted at 100 mcg/mL, a 0.4 mL injection equals 40 mcg
- Always verify supplier's concentration before calculating doses
Cycling & Timing
Why Cycling Matters
Continuous exposure to IGF-1 LR3 induces receptor desensitization, reducing efficacy over time. Cycling also minimizes oncogenic risk from sustained mitogenic signaling.
Standard Cycling Protocol
4-Week Cycle (Beginner-Friendly):
- 4 weeks on (20–50 mcg daily)
- 2 weeks off
- Repeat